Fig. 6 AV3 potentiates the effect of gemcitabine in the PDX model in mice. AV3 potentiates the effect of gemcitabine in the PDX model in mice. (A) Schematic representation of the generation of the human pancreatic PDX tumor model. (B) Tumor growth curves in the PDX model after the treatment with vehicle, AV3 (20 mg/kg, intraperitoneally, twice a week), gemcitabine, or AV3 + Gem. The doses of AV3 and Gem were 20 and 50 mg/kg, respectively, intraperitoneally, biweekly, starting at day 0. Data represent means ± SEM. n = 5 mice per group. *P < 0.05 and **P < 0.01. (C) Images of the isolated tumors and (D) tumor weights at the end of the experiment. (E) NIR imaging showing the accumulation of ICG dye in tumors treated with either vehicle or AV3. The degree of ICG fluorescence signal was quantified. n = 5 mice per group. Data represent means ± SEM. (F) Microscopic pictures of immunohistochemical staining of collagen I and CD31, and CD31 lumen size quantitation. Data represent means ± SEM. *P < 0.05 and **P < 0.01. Praneeth R. Kuninty et al. Sci Adv 2019;5:eaax2770 Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).